Management and survival in advanced prostate cancer in Nairobi

East African Medical Journal

Volumn 77, Issue 5, 2000, Pages 260-263

  Magoha, G A O ^a  

^a UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; HUMAN; KENYA; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; KENYA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0034178102     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Parker, S. L., Tong T, Boldoen, S., and Wingo, P.A. Cancer statistics 1996. CA. Cancer J. Clin. 1996; 46: 5-7.
2. Masters, J.G., Keegan, P.E., Hildreth, A.J. and Green, D.R.J. Free/Total serum prostate specific antigen ratio: How helpful is it in detecting prostate cancer? Brit. J. Urol. 1998; 81: 419-23.
3. Deamaley, D.P. Cancer of the prostate. Brit. Med. J. 1994; 308: 780 - 784.
4. Yeboah, E.D. and Quartey J. K.M. Low dosage stilboestrol in the management of carcinoma of the prostate. Ghana. Med. J. 1977; 16: 13-15.
5. Nkposong, E.O. and Lawani, J. Primary carcinoma of the prostate in Ibadan W. Afri. Med. J. 1983; 22: 108-111.
6. Udeh, F. N. Prostatic carcinoma in Nigeria - A ten year retrospective study. J. Int. Urol. Nephrol. 1981; 13: 159-161.
7. Magoha, G.A.O. Subcapsular orchidectomy in the management of prostatic cancer in Nigerians, East Afr. Med. J. 1989; 66: 400 - 403.
8. Magoha, G.A.O. Epidemiological and clinical aspects of incidental carcinoma of the prostate in African: Experience at the Lagos University Teaching Hospital, Lagos and the Kenyatta National Hospital, Nairobi, East Afr. Med. J. 1995; 72: 283-287.
9. Catalona W.J., Smith P.S., Batriff, T.L. and Basler J.W. Detection of organ confined prostate cancer is increased through prostate specific antigen based screening.
10. Boyle, P., Malsonneuve P. and Napalkov, O. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 1995; 46: 47 - 55.
11. Schroeder F.H. and Boyle P. Screening of prostate cancer - Necessity or nonsence? Europ. J. Cancer 1993; 29A: 656 - 661.
12. Whitemore A.S., Kolonel, L.N. and Wu A.H. et al Prostate cancer in blacks. whites and Asians in the United States and Canada. J. Natl. Cancer Inst 1995; 87: 652-661
13. Dunn, J.E. Cancer epidemiology in populations of the United States with emphasis on Hawii, California and Japan. Cancer Res. 1975; 35: 3240-3242.
14. Cannon, L., Bishop, D.T., Skolnic, M., Hunt, S. and Lyon, J.L. and Smart C.R. Genetic epidemiology of prostate cancer in Utah Mormon Geneology. Cancer Surv. 1982; 1: 47-69.
15. Brawn, P.N. Johnson, E.H. and Kuhl, D.L. et al. Stage at presentation and survival of white and black patients with prostate carcinoma. Cancer 1993; 2569-2573.
16. Stamey, T.A. Freiha, F.S., McNeal, J.F., Redwine, F.A., Whitemore, A.S. and Schmid, H.P. Localized prostate cancer: Relationship of tumour volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71: 993 - 938
17. Terris M.K; McNeal J.F. and Stamey T.A. Detection of clinically significant prostate cancer by transurethral ultrasound guided systemic biopsies. J. Urol. 1992; 148: 829-832.
18. Lange, P.H. and Narayan, P. Understaging and undergrading of prostate cancer. Urology, 1983; 21: 113-118.
19. Zincke, H., Oesterling, J.E., Blute, M.L., Bergstrahl, E.J., Myers, R.P. and Barret, D.M. Long term (15 years) results after radical prostatectomy for clinically localized (stage T2C or lower) prostate cancer. J. Urol. 1994; 152: 1 850-1 857
20. Higgins, C. and Hodges, C.L. Studies on prostatic cancer - The effect of castration on clinical patients with carcinoma of the prostate. Arch. Surg. 1941; 43: 209-df.
21. Cranford, E.D. and Nabors, W. Hormone therapy of advanced prostate cancer: Where we stand today? Oncology 1991; 5: 21 -30.
22. Stege, R., Calstrom, K., Von Schoultz, B. et al. Single dose parenteral oestrogen treatment in prostatic cancer: A study of two maintenance regimens. The prostate 1989; 14: 183-188.
23. Labrie, F., Belanger, A. and Labrie, C. et al. Science behind total androgen blockade: From gene to combination therapy. Clin. Inv. Med. 19991; 16:475-492.
24. Kerle, D., Williams, G., Ware, H. and Bloom, S.R. Failure of long term lutenizing hormone releasing hormone treatment for prostatic cancer to suppress serum lutenizing hormone and testosterone. Brit. Med. J. 1994; 289: 468 - 469.
25. Williams, G., Kerle, D., Griffin, S., Dunlop, H. and Bloom, S.R. Biodegradable polyrner lutenizing hormone releasing hormone analogue for prostate cancer: Use of a new peptide delivery system. Brit. Med. J. 1994; 289: 1580-1581.
26. Turkes, A., Turkes, A., Peeling, B. and Griffiths, K. The use of LHRH analogue zoladex in the treatment of prostate cancer: A dose interval study. Med. Sci. Res. 1987; 1: 477
27. Dennis, L.J., Whelan, P, and Carneiro, D.E. Moura, J.L. Goserelin acetate and flutamide versus bilateral orchidectomy: A phase III EORTC trial (30853), 130. Urology 1993; 42: 119-130.
28. Janknegt, R.A., Abbou, C.C. and Bartoletti, R. Orchirdectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double blind randomizes trial. J. Urol. 1993; 149: 77 - 83.
29. Bertagna, C., De Gery, A. Hucher, M. et al. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostate cancer. Ameta-analysis of seven randomised double blind trials. Brit. J. Urol. 1994; 73: 396 - 402.
30. Frydenberger, M., Strincker, P.D. and Kaye, K.W. Prostate cancer diagnosis and management. Lancet 1997; 349: 1681 - 1687.
31. Adolfsson, J., Cartensen, T. and Lowhagen, T. Differed treatment in localized prostate cancer. Brit. J. Urol. 1992; 69: 183 - 187.
32. Johanson, J.E., Adami, H.O., Anderson, S.O., Bergstrom, R., Homberg, L. and Krusemo, U.B. High 10 year survival rate in patients with early untreated prostate cancer. J. Amer. Med. Ass. 1992; 267: 2191-2196.
33. Wallace, D.M., Chisholm, G.D and Hendry, W.F TNM Classification of urological tumours. Brit. J. Urol. 1975; 47: 172-175
34. Bailer, J.C III., Mellinger, G.T. and G. leason D.F. Survival rates of patients with prostate cancer tumour grade and differentiation. Cancer Chemother Rep. 1972; 50: 129-132.
35. Mostofi, F.K. Grading of prostatic carcinoma. Cancer Chemother Rep. 1975; 59: 113.
36. Gaeta, J.F., Asiwartham, J.E., Miller, E. and Murphy, G.P. Histologic grading of primary prostatic cancer. A new approach to an old problem. J. Urol. 1980; 123: 689-692.
37. Bocking, A., Kiehn, J. and Heinzel-Wach, M. Combined histologic grading of prostatic carcinoma. Cancer; 1982; 50: 288-290.
38. Histologieal grading of prostate cancer. The development of a new system and comparison with other methods. Cancer. 1 982; 49: 525-528.
39. Stamey, T.A., Freiha, F.S., Redwine, E. A., et al. Localized prostate cancer. Cancer 1993; 71: 93-98.
40. Kabalin, J.N., MeNeal, J.E., Jonstone, I.M. and Stamey, T.A. Serum prostate specific antigen and biologic progression of prostate cancer. Urology 1995; 46: 65-70.
41. Plock, N.R. and Brawer M.K How to use prostate specific antigen. Urology 1994; 43: 27-35.
42. Sharife, R., Soloway, M. and the leuprolide study group: Clinical study of leuprolide depot in the treatment of advanced prostate cancer. J. Urol. 1990; 143: 68-71.
43. Dearnalley, D.P., Bayly, R.J. and Ahern, R.P. Palliation of bone metastases in prostate cancer, hemibody radiation or strontium-89? Clin. Oncol. 1992; 4: 101-107.
44. Bolger, J.J. Dearnaley, D.P. and Kirk, D. UK (metastron) investigators group: Strontiurn-89 [metastrom] versus external beam Radiotherapy in patients with painful bone metastases secondary to prostatic cancer. Sem. Oncol. 1993; 20: 32-33.